2098 ORAL BCIRG 007: First overall survival analysis of randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer (MBC)

Authors :: Wolfgang Eiermann
G. von Minckwitz
V. Valero
Tadeusz Pienkowski
M. Martin
Mark D. Pegram
John F. Forbes
J.P. Crown
Source :: European Journal of Cancer Supplements. 5:212-213
Publication Year :: 2007
Publisher :: Elsevier BV, 2007.

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
business.industry
medicine.disease
Metastatic breast cancer
Carboplatin
chemistry.chemical_compound
First line therapy
Docetaxel
chemistry
Trastuzumab
Internal medicine
Overall survival
Medicine
business
medicine.drug

Tools